Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent
treatment strongly predicts recurrence in multiple tumor types, but whether further treatment …

Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors
(ICIs) can produce remarkably durable responses, most patients develop early disease …

PURPOSE The aim of this joint guideline is to provide evidence-based recommendations to
practicing physicians and other health care providers on integrative approaches to …

Background Patients with cancer have complex physical, psychosocial, and spiritual needs
that evolve throughout their disease trajectory. As patients are living longer with a diagnosis …

This study shows that mutations in KEAP1 and NFE2L2 predict for LR after radiotherapy but
not surgery in patients with NSCLC. Approximately half of all LRs are associated with these …

Purpose: Activation of NFE2L2 has been linked to chemoresistance in cell line models.
Recently, somatic mutations that activate NFE2L2, including mutations in NFE2L2, KEAP1, or …

Introduction Targeted therapies have transformed treatment of driver-mutated metastatic
NSCLC. We compared cardiovascular adverse events between and within targeted therapy …

Introduction Despite the recent advance of consolidation durvalumab in the treatment of
unresectable stage III NSCLC, not every patient benefits from durvalumab and the predictive …

Introduction Leptomeningeal carcinomatosis (LM) is a severe complication of non–small-cell
lung cancer (NSCLC) historically associated with poor prognosis. New chemotherapeutic …

Background: ASCO and IOM recommend palliative care (PC) across health care settings for
patients with serious illnesses, including cancer. This study provides an overview of the …